Lifecore Biomedical (LFCR) said Tuesday it has signed a new 10-year commercial manufacturing and supply agreement with an existing customer.
Financial terms weren't disclosed, and Lifecore didn't identify the customer.
The company said the deal is the latest between the two firms to support the advancement of a new ophthalmic therapy from clinical development to the market.
In conjunction with the agreement, Lifecore said it has also signed a multi-million-dollar statement of work detailing a range of fill-and-finish services that include manufacturing batches of the drug candidate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.